Seçil Azime Karakuş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seçil Azime Karakuş has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ceren Önal
Department of Anesthesiology and Reanimation, Ağrı Research and Training Hospital, Ağrı 04200, Türkiye
3 shared publications - Ayten Saracoglu
Department of Anesthesiology, University of Florida, UF Health, Jacksonville, FL 32209, USA
2 shared publications - Eray Metin Guler
Department of Medical Biochemistry, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul, Turkey
2 shared publications - Kemal Tolga Saraçoğlu
Department of Anaesthesiology, ICU & Perioperative Medicine, Hazm Mebaireek General Hospital HMC, Qatar University College of Medicine, Doha P.O. Box 2713, Qatar
2 shared publications - Paweł Ratajczyk
Department of Anesthesiology and Intensive Therapy, Medical University of Lodz, 90-153 Lodz, Poland
2 shared publications - Tomasz Gaszynski
Medical University of Lodz
2 shared publications
Latest Publications
- Open Access
- 29 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1074
Investigation of the Effect of Amniomax on Lidocaine-Induced Toxicity in Healthy Colon Cell Culture
Background: Lidocaine (LIDO) toxicity is a critical concern in regional anesthesia, with no specific antidote currently available. While lipid emulsions are commonly used as rescue agents in cases of local anesthetic systemic toxicity (LAST), their efficacy is inconsistent, and their safety remains controversial. AmnioMax® (AMX), a specialized cell culture medium enriched with growth factors and bioactive molecules, has the potential to offer cytoprotective effects. This study aims to investigate the therapeutic efficacy of AMX in mitigating lidocaine-induced cytotoxicity and to explore its protective mechanisms at the cellular level. Methods: Healthy colon cells (CCD-18Co) were used in this study. Four experimental groups were established as follows: control, LIDO, AMX, and LIDO + AMX. Cellular viability in the control group was set at 100%. LIDO was administered at concentrations ranging from 0.06 to 10%, AMX at 0.625–100%, and LIDO + AMX at 60% of the half-maximal effective concentration (EC50) combined with LIDO (0.06–10%). Cells were incubated for 24 h, after which cellular viability, DNA damage, apoptosis, intracellular reactive oxygen species (iROS), intracellular calcium (Ca), mitochondrial membrane potential (MMP), and glutathione (GSH) were evaluated. Results: LIDO exposure led to a concentration-dependent decrease in viability compared to the control group (p < 0.001), while AMX significantly increased viability (p < 0.001). In the LIDO + AMX group, viability was also reduced (p < 0.001); however, cytotoxicity was significantly lower than in the LIDO group (p < 0.05). Both the LIDO and LIDO + AMX groups showed increased iROS levels, DNA damage, and apoptosis (p < 0.001), along with the decreased MMP and GSH levels (p < 0.001) compared to the control. However, in the LIDO + AMX group, iROS, DNA damage, and apoptosis were significantly lower than in the LIDO group (p < 0.01), MMP levels were increased (p < 0.001), and no significant difference was observed in GSH levels. Conclusions: AMX demonstrated cytoprotective effects against LIDO-induced cytotoxicity, suggesting its potential as an alternative therapeutic agent for LAST.
- 29 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1074
Open AccessInvestigation of the Effect of Amniomax on Lidocaine-Induced Toxicity in Healthy Colon Cell Culture
Background: Lidocaine (LIDO) toxicity is a critical concern in regional anesthesia, with no specific antidote currently available. While lipid emulsions are commonly used as rescue agents in cases of local anesthetic systemic toxicity (LAST), their efficacy is inconsistent, and their safety remains controversial. AmnioMax® (AMX), a specialized cell culture medium enriched with growth factors and bioactive molecules, has the potential to offer cytoprotective effects. This study aims to investigate the therapeutic efficacy of AMX in mitigating lidocaine-induced cytotoxicity and to explore its protective mechanisms at the cellular level. Methods: Healthy colon cells (CCD-18Co) were used in this study. Four experimental groups were established as follows: control, LIDO, AMX, and LIDO + AMX. Cellular viability in the control group was set at 100%. LIDO was administered at concentrations ranging from 0.06 to 10%, AMX at 0.625–100%, and LIDO + AMX at 60% of the half-maximal effective concentration (EC50) combined with LIDO (0.06–10%). Cells were incubated for 24 h, after which cellular viability, DNA damage, apoptosis, intracellular reactive oxygen species (iROS), intracellular calcium (Ca), mitochondrial membrane potential (MMP), and glutathione (GSH) were evaluated. Results: LIDO exposure led to a concentration-dependent decrease in viability compared to the control group (p < 0.001), while AMX significantly increased viability (p < 0.001). In the LIDO + AMX group, viability was also reduced (p < 0.001); however, cytotoxicity was significantly lower than in the LIDO group (p < 0.05). Both the LIDO and LIDO + AMX groups showed increased iROS levels, DNA damage, and apoptosis (p < 0.001), along with the decreased MMP and GSH levels (p < 0.001) compared to the control. However, in the LIDO + AMX group, iROS, DNA damage, and apoptosis were significantly lower than in the LIDO group (p < 0.01), MMP levels were increased (p < 0.001), and no significant difference was observed in GSH levels. Conclusions: AMX demonstrated cytoprotective effects against LIDO-induced cytotoxicity, suggesting its potential as an alternative therapeutic agent for LAST.
- Open Access
- 15 October 2024
- Published by Springer Nature in BMC Anesthesiology
- Vol. 24 (1) , 1-14
Comparative efficacy of ultrasound-guided erector spinae plane block versus wound infiltration for postoperative analgesia in instrumented lumbar spinal surgeries
This study compared the efficacy of ultrasound-guided erector spinae plane block (ESPB) and wound infiltration (WI) for postoperative analgesia in patients who underwent lumbar spinal surgery with instrumentation. In this randomized controlled trial, 80 patients were divided into two groups: ESPB (n = 40) and WI (n = 40). Postoperative pain intensity was assessed via the visual analog scale (VAS) at multiple time points within 24 h. Additionally, opioid consumption, time to first rescue analgesia, incidence of postoperative nausea and vomiting (PONV), and patient satisfaction were evaluated. Both ESPB and WI provided effective postoperative pain management, with no significant differences in VAS scores. However, the ESPB group demonstrated a significantly longer duration of analgesia, a shorter time to first rescue analgesia, and lower total tramadol consumption (50 ± 60 mg vs. 100 ± 75 mg; p = 0.010) than did the WI group. Furthermore, a trend toward reduced PONV incidence was observed in the ESPB group, likely due to its opioid-sparing effect. While both ESPB and WI provided effective postoperative pain management, ESPB demonstrated a distinct advantage by offering a longer duration of analgesia and significantly reducing opioid consumption. These findings suggest that ESPB is more effective than WI for postoperative analgesia in lumbar spinal surgeries, providing prolonged pain relief and improving patient outcomes. Further studies are warranted to explore its long-term benefits and cost-effectiveness. ClinicalTrials.govPRS: NCT06567964 Date: 08/21/2024 Retrospectively registered. 1. Study Objective: This study aimed to compare the efficacy of ultrasound-guided erector spinae plane block (ESPB) with that of wound infiltration (WI) for postoperative analgesia in lumbar spinal surgeries involving instrumentation. 2. Primary outcome: Postoperative pain intensity was measured via the visual analog scale (VAS) at multiple time points. The VAS scores were comparable between ESPB and WI at all assessed time points, indicating no significant differences in pain scores. However, both techniques still played a role in postoperative pain management. 3. Opioid consumption: ESPB was associated with a significant reduction in total tramadol consumption compared with WI, indicating that an opioid-sparing effect that could reduce the risk of opioid-related side effects. 4. Duration of Analgesia: Patients in the ESPB group experienced a longer duration before requiring rescue analgesia, suggesting that ESPB provides more prolonged pain relief than WI does. 5. Side Effects and Patient Satisfaction: The incidence of postoperative nausea and vomiting (PONV) was lower in the ESPB group, potentially due to reduced opioid consumption. These findings suggest that ESPB may increase patient satisfaction and comfort during the postoperative period. 6. Clinical Implications: These findings support the integration of ESPB into multimodal analgesia protocols for lumbar spinal surgeries, given its potential advantages in reducing opioid consumption and providing extended pain relief. 7. Limitations: This study has several limitations. First, although the sample size was calculated based on a power analysis and was sufficient to detect significant differences in the primary outcomes, a larger sample size might provide more robust insights into secondary outcomes or less common side effects. Additionally, the study was conducted at a single center, which may limit the generalizability of the findings. Future multicenter studies are needed to validate these results across diverse patient populations and clinical practices. Lastly, the follow-up period was limited to 24 h, which does not allow for the assessment of long-term outcomes such as chronic pain development or functional recovery. 8. Future research: Further studies are recommended to explore the long-term benefits of ESPB, its cost-effectiveness, and its potential integration into enhanced recovery protocols (ERASs) for surgical patients.
- 15 October 2024
- Published by Springer Nature in BMC Anesthesiology
- Vol. 24 (1) , 1-14
Open AccessComparative efficacy of ultrasound-guided erector spinae plane block versus wound infiltration for postoperative analgesia in instrumented lumbar spinal surgeries
This study compared the efficacy of ultrasound-guided erector spinae plane block (ESPB) and wound infiltration (WI) for postoperative analgesia in patients who underwent lumbar spinal surgery with instrumentation. In this randomized controlled trial, 80 patients were divided into two groups: ESPB (n = 40) and WI (n = 40). Postoperative pain intensity was assessed via the visual analog scale (VAS) at multiple time points within 24 h. Additionally, opioid consumption, time to first rescue analgesia, incidence of postoperative nausea and vomiting (PONV), and patient satisfaction were evaluated. Both ESPB and WI provided effective postoperative pain management, with no significant differences in VAS scores. However, the ESPB group demonstrated a significantly longer duration of analgesia, a shorter time to first rescue analgesia, and lower total tramadol consumption (50 ± 60 mg vs. 100 ± 75 mg; p = 0.010) than did the WI group. Furthermore, a trend toward reduced PONV incidence was observed in the ESPB group, likely due to its opioid-sparing effect. While both ESPB and WI provided effective postoperative pain management, ESPB demonstrated a distinct advantage by offering a longer duration of analgesia and significantly reducing opioid consumption. These findings suggest that ESPB is more effective than WI for postoperative analgesia in lumbar spinal surgeries, providing prolonged pain relief and improving patient outcomes. Further studies are warranted to explore its long-term benefits and cost-effectiveness. ClinicalTrials.govPRS: NCT06567964 Date: 08/21/2024 Retrospectively registered. 1. Study Objective: This study aimed to compare the efficacy of ultrasound-guided erector spinae plane block (ESPB) with that of wound infiltration (WI) for postoperative analgesia in lumbar spinal surgeries involving instrumentation. 2. Primary outcome: Postoperative pain intensity was measured via the visual analog scale (VAS) at multiple time points. The VAS scores were comparable between ESPB and WI at all assessed time points, indicating no significant differences in pain scores. However, both techniques still played a role in postoperative pain management. 3. Opioid consumption: ESPB was associated with a significant reduction in total tramadol consumption compared with WI, indicating that an opioid-sparing effect that could reduce the risk of opioid-related side effects. 4. Duration of Analgesia: Patients in the ESPB group experienced a longer duration before requiring rescue analgesia, suggesting that ESPB provides more prolonged pain relief than WI does. 5. Side Effects and Patient Satisfaction: The incidence of postoperative nausea and vomiting (PONV) was lower in the ESPB group, potentially due to reduced opioid consumption. These findings suggest that ESPB may increase patient satisfaction and comfort during the postoperative period. 6. Clinical Implications: These findings support the integration of ESPB into multimodal analgesia protocols for lumbar spinal surgeries, given its potential advantages in reducing opioid consumption and providing extended pain relief. 7. Limitations: This study has several limitations. First, although the sample size was calculated based on a power analysis and was sufficient to detect significant differences in the primary outcomes, a larger sample size might provide more robust insights into secondary outcomes or less common side effects. Additionally, the study was conducted at a single center, which may limit the generalizability of the findings. Future multicenter studies are needed to validate these results across diverse patient populations and clinical practices. Lastly, the follow-up period was limited to 24 h, which does not allow for the assessment of long-term outcomes such as chronic pain development or functional recovery. 8. Future research: Further studies are recommended to explore the long-term benefits of ESPB, its cost-effectiveness, and its potential integration into enhanced recovery protocols (ERASs) for surgical patients.
- Open Access
- 24 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1652
Investigation of the Protective Effects of Magnesium on Bupivacaine-Induced Toxicity at the Level of Colon Cell Culture
The primary objective of this in vitro study was to prevent the risk of toxicity associated with bupivacaine, widely used in clinical practice, by using magnesium (Mg), a readily available and cost-effective element, as an adjuvant. We hypothesized that Mg might exhibit a protective effect against cytotoxicity in a colon cell culture model under conditions of bupivacaine-induced LAST. Our secondary aim was to investigate its effect on genotoxicity, apoptosis, and iROS. CCD-18Co cells were used in our study. Control group (group C), Bupivacaine group (group B), Magnesium group (group M), and Bupivacaine+Mg group (group BM) were created. The viability of CCD-18Co cells incubated for 24 h in group C was determined to be 100%. These cells were evenly divided, and bupivacaine was administered to group B at concentrations of 5 to 300 μM. In group M, doses of Mg at 0.625 to 320 mEq were added. It was determined that the maximum viability was observed at a Mg dose of 40 mEq (p < 0.05). In group BM, bupivacaine was administered at the same concentrations in combination with Mg (40 mEq), and cell viability was measured. DNA damage, apoptosis, and iROS were assessed at concentrations of bupivacaine by administering 40 mEq Mg. In group B, viability decreased dose-dependently in CCD-18Co (p < 0.05, p < 0.01, p < 0.001). In group BM, the viability decreased in cells at increasing concentrations compared to group C (p < 0.05, p < 0.01, p < 0.001), but the viability was affected positively compared to group B (p < 0.05). In group B, DNA damage increased (p < 0.05, p < 0.001). In group BM, DNA damage increased (p < 0.05, p < 0.001). However, in group BM, DNA damage levels were reduced compared to group B (p < 0.05, p < 0.01). In group B, apoptosis increased (p < 0.05, p < 0.001); in group BM, apoptosis increased (p < 0.001) compared to group C. However, in group BM, apoptosis decreased compared to group B (p< 0.05). iROS increased in group B (p < 0.05, p < 0.01, p < 0.01) and group BM (p < 0.05, p < 0.01, p < 0.001) compared to the group C. However, in group BM, iROS decreased in comparison to group B (p < 0.05). In conclusion, Mg exhibits a protective effect against bupivacaine-induced toxicity.
- 24 July 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1652
Open AccessInvestigation of the Protective Effects of Magnesium on Bupivacaine-Induced Toxicity at the Level of Colon Cell Culture
The primary objective of this in vitro study was to prevent the risk of toxicity associated with bupivacaine, widely used in clinical practice, by using magnesium (Mg), a readily available and cost-effective element, as an adjuvant. We hypothesized that Mg might exhibit a protective effect against cytotoxicity in a colon cell culture model under conditions of bupivacaine-induced LAST. Our secondary aim was to investigate its effect on genotoxicity, apoptosis, and iROS. CCD-18Co cells were used in our study. Control group (group C), Bupivacaine group (group B), Magnesium group (group M), and Bupivacaine+Mg group (group BM) were created. The viability of CCD-18Co cells incubated for 24 h in group C was determined to be 100%. These cells were evenly divided, and bupivacaine was administered to group B at concentrations of 5 to 300 μM. In group M, doses of Mg at 0.625 to 320 mEq were added. It was determined that the maximum viability was observed at a Mg dose of 40 mEq (p < 0.05). In group BM, bupivacaine was administered at the same concentrations in combination with Mg (40 mEq), and cell viability was measured. DNA damage, apoptosis, and iROS were assessed at concentrations of bupivacaine by administering 40 mEq Mg. In group B, viability decreased dose-dependently in CCD-18Co (p < 0.05, p < 0.01, p < 0.001). In group BM, the viability decreased in cells at increasing concentrations compared to group C (p < 0.05, p < 0.01, p < 0.001), but the viability was affected positively compared to group B (p < 0.05). In group B, DNA damage increased (p < 0.05, p < 0.001). In group BM, DNA damage increased (p < 0.05, p < 0.001). However, in group BM, DNA damage levels were reduced compared to group B (p < 0.05, p < 0.01). In group B, apoptosis increased (p < 0.05, p < 0.001); in group BM, apoptosis increased (p < 0.001) compared to group C. However, in group BM, apoptosis decreased compared to group B (p< 0.05). iROS increased in group B (p < 0.05, p < 0.01, p < 0.01) and group BM (p < 0.05, p < 0.01, p < 0.001) compared to the group C. However, in group BM, iROS decreased in comparison to group B (p < 0.05). In conclusion, Mg exhibits a protective effect against bupivacaine-induced toxicity.